title: Experience with use of Zostavax(®) in patients with hematologic malignancy and hematopoietic cell transplant recipients.
authors: Oregon Health and Sciences University School of Medicine, USA.
authors: Elliot
authors: E
authors: Naidus
authors: Lloyd
authors: L
authors: Damon
authors: Brian S
authors: BS
authors: Schwartz
authors: Cheryl
authors: C
authors: Breed
authors: Catherine
authors: C
authors: Liu
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019072:Antibiotic Prophylaxis; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000276:immunology / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006562:Herpes Zoster / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D053061:Herpes Zoster Vaccine; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged
chemical_list: D000914:Antibodies, Viral; D053061:Herpes Zoster Vaccine; D007074:Immunoglobulin G; D000212:Acyclovir